Lifestyle Medicine Is at a Tipping Point in the US, Expert Says, and It Could Be Just in Time
Without a shift in the approach to disease prevention and management in the US, the health system won't be able to handle the burden of our morbidity, says Richard Rosenfeld, MD, MPH, MBA.
Weight Loss Achievable Despite Interruptions in GLP-1 Medication Access, Study Finds
ENDO 2025. People with inconsistent access to GLP-1 medications still achieved clinically significant weight loss when therapy was combined with lifestyle changes and coaching.
New Guidelines Recommend Preconception Screening in Diabetes, Universal Testing for Primary Aldosteronism
ENDO 2025: The publications reflect growing consensus that integration of endocrine screening into standard clinical workflows is essential for early risk detection and long-term disease prevention.
Dupilumab Sustains Long-Term Reduction of S. aureus in People with AD: Daily Dose
Your daily dose of the clinical news you may have missed.
Obesity Redefined: 1 in 5 Adults Reclassified Under New EASO Criteria
Individuals newly classified with obesity using the European framework were found to be overall sicker and at greater risk for mortality.
Q&A: GLP-1 Monotherapy Is Not Enough—Jonathan Bonnet, MD, MPH, on the Lifestyle Prescription for Obesity
Obesity medicine expert Bonnet answers questions about the downsides of GLP-1 therapy for obesity management and how lifestyle medicine interventions will help.
"Everyone is a Candidate for Some Positive Lifestyle Change," Guideline Author Suggests
Richard Rosenfeld, MD, MPH, MBA, led the development of lifestyle medicine guidelines to treat or even reverse prediabetes and type 2 diabetes.
Population-Wide Study Finds No Link Between Aluminum Exposure in Vaccines and Childhood Disorders
The Danish study analyzed a nationwide cohort of 2.1 million children and found no association between aluminum exposure and allergic, autoimmune, or neurodevelopmental conditions.
Lebrikizumab Found Safe, Effective in Patients With Skin of Color With AD: Daily Dose
ENDO 2025: Most Patients With Classic Congenital Adrenal Hyperplasia Experience High Glucocorticoid Exposure or Suboptimal Control
A new analysis of the CAHtalog phase 3 study showed approximately 95% of participants experienced either high glucocorticoid exposure or elevated androstenedione levels during treatment.
The Role of Stress Reduction in Cardiometabolic Disease Management for Patients with Obesity
Monu Khanna, MD, discusses the benefits of behavioral strategies, including yoga, breathwork, and dancing, in reducing cardiovascular disease risk in patients with obesity.
Turn Therapeutics Launches First Clinical Trial to Assess Topical IL-36 Inhibitor for Atopic Dermatitis
GX-03 has proven effective in preclinical trials, reducing disease severity by more than 50% vs placebo. Data from the current study are expected by year end.
Maternal Depression Impairs Parental Emotional Responsiveness, Daily Care for Infants, Children: Global Systematic Review
Maternal depression significantly disrupts parenting behaviors, impacting child development and emotional bonding, according to an updated international literature review.
Lifestyle Medicine Guidelines for T2D, Prediabetes Are the Result of Remarkable Collaboration Across Specialties
Lead author for the American College of Lifestyle Medicine's new clinical practice guideline discusses the broad endorsement for the recommendations across participating groups.
Monu Khanna, MD: Essential Lifestyle Changes for Managing Obesity and Cardiometabolic Risk Factors
Obesity-Related Cancer Deaths More Than Tripled in the US from 1999 to 2020
ENDO 2025. Older adults, rural populations, and residents in the Midwest experienced the highest mortality rates, according to new data.
FDA to Review GSK's Application for Expanded Use of RSV Vaccine in High-Risk Adults Aged 18 to 49
GSK's RSV vaccine Arexvy would join shots from Pfizer and Moderna for the younger adult population, broadening choice for those with risk factors for severe disease.
FDA Approves Finerenone for Heart Failure With LVEF ≥40% Following Positive Phase 3 Data
FDA approval based on FINEARTS-HF trial showing 16% risk reduction in CV death and HF events.
AstraZeneca's Aldosterone Inhibitor Baxdrostat Effective Against Resistant HTN in Late-Stage Trial
Baxdrostat met the primary and all secondary endpoints, setting up a first regulatory filing for the selective aldosterone synthase inhibitor, according to AstraZeneca.
Treatment Options for Obesity-Related Cardiometabolic Diseases: Clinician Insights for Primary Care
Treatment should address root causes, including lifestyle modifications, stress management, and gut health, Monu Khanna, MD, told Patient Care.
